Skip to content

Routine Mucosal Hemostasis with Argon Plasma Coagulation or Hot Forceps in Endoscopic Submucosal Dissection for Early Gastric Cancer and Gastric Intraepithelial Neoplasia : A randomized Controlled Trial

Routine Mucosal Hemostasis with Argon Plasma Coagulation or Hot Forceps in Endoscopic Submucosal Dissection for Early Gastric Cancer and Gastric Intraepithelial Neoplasia : A randomized Controlled Trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000032995
Enrollment
Unknown
Registered
2020-05-17
Start date
2020-06-01
Completion date
Unknown
Last updated
2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early gastric cancer and gastric intraepithelial neoplasia

Interventions

Group 1:APC
Group 2:Hot forceps

Sponsors

Shenzhen People's Hospital (the Second Clinical Medical College of Jinan University, the First Affiliated Hospital of South University of science and Technology)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The patients with early gastric cancer and precancerous lesions confirmed by preoperative gastroscopy and biopsy are in line with ESD indications; 2. The patients who had the first gastric mucosa stripping; 3. Patients aged 20-80 years, male and female; 4. Patients who sign the written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with previous history of acute myocardial infarction (within 6 months) and severe heart, liver and kidney dysfunction or mental disorders; 2. Patients taking aspirin, warfarin and other anticoagulants, or patients with coagulation dysfunction; 3. To identify the patients with early gastric cancer with lymph node metastasis; 4. Patients with cancer invading the intrinsic myometrium; 5. Patients with concurrent cancer, isochronous cancer or postoperative residual cancer; 6. Patients after subtotal gastrectomy; 7. Pregnant women; 8. Patients with other tumors; 9. Patients who do not sign informed consent or do not have the ability to sign informed consent; 10. Patients who are participating in other clinical observation trials or have participated in other clinical trials within 60 days.

Design outcomes

Secondary

MeasureTime frame
Visual analogur score;R0 resection rate;En bloc resection rate;Length of hospital stay;Operation time;Hospitalization expense;

Primary

MeasureTime frame
Complication rate;Prophylactic endoscopic coagulation time;

Countries

China

Contacts

Public ContactLisheng Wang

Shenzhen People's Hospital (the Second Clinical Medical College of Jinan University, the First Affiliated Hospital of South University of science and Technology)

wangls168@163.com+86 13714725662

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026